Abstract
Objective Limited research links hospital-based experiences of skin-to-skin (STS) care to longer-term neurodevelopmental outcomes in preterm children. The present study examined relations between inpatient STS and neurodevelopmental scores measured at 12 months in a sample of very preterm (VPT) infants.
Study Design and Methods From a retrospective study review of medical records of 181 VPT infants (<32 weeks gestational age (GA)) we derived the STS rate, i.e., the total minutes of STS each infant received/day of hospital stay. We used scores on the Capute Scales from routine follow-up care at 12 months as the measure of neurodevelopmental outcome (n=181).
Results Families averaged approximately 17 minutes/day of STS care (2 days/week, 70 minutes/session), although there was substantial variability. Variation in STS rate was positively associated with outcomes at 12 months corrected age (r = 0.25, p < .001). STS rate significantly predicted 6.2% unique variance in 12-month neurodevelopmental outcomes, after controlling for GA, socioeconomic status (SES), health acuity, and visitation frequency. A 20-minute increase in STS per day was associated with a 10-point increase (.67 SDs) in neurodevelopmental outcomes at 12 months. SES, GA, and infant health acuity did not moderate these relations.
Conclusion VPT infants who experienced more STS during hospitalization demonstrated higher scores on 12-month assessments of neurodevelopment. Results provide evidence that STS care may confer extended neuroprotection on VPT infants through the first year of life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research work was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K.E. Travis, PI: 5R00-HD8474904; H.M. Feldman, PI: 2R01-HD069150) and the National Institute of Mental Health Postdoctoral Research Training in Child Psychiatry and Neurodevelopment (A. Reiss, PI: T32-MH019908).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Stanford University Institutional Review Board gave ethical approval for this work (#IRB-44480).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We initially reported this relation in a sample of 37 very preterm infants for whom we had 12 month neurodevelopmental assessments. However, the small amount of participants with neurodevelopmental follow-up at 12 months seemed a primary concern to reviewers. To address this issue, we have substantially increased our sample to include n=181 infants with 12 month neurodevelopment assessments, an almost 5-fold increase in sample size. In this much larger sample, we replicate our initial findings showing the unique predictive power of skin-to-skin care to 12 month neurodevelopmental outcomes over covariates. The fact that we observe the same pattern of findings, we believe, speaks to the robustness and generalizability of our findings.
Data Availability
Deidentified individual participant data will be made available upon request.
